共 50 条
Clinical pharmacology confounders in older adults
被引:0
|作者:
Sitar, Daniel S.
[1
,2
]
机构:
[1] Univ Manitoba, Dept Pharmacol & Therapeut, Ctr Aging, Dept Internal Med,Clin Pharmacol Sect, Winnipeg, MB, Canada
[2] Univ Manitoba, Dept Pharmacol & Therapeut, Fac Med, Winnipeg, MB R3E 0T6, Canada
关键词:
aging;
biomarkers of disease;
drug therapy;
ethics;
polypharmacy;
research considerations;
MEDICATION USE;
AGE;
PHARMACODYNAMICS;
DISPOSITION;
INHIBITION;
PREVALENCE;
PREVENTION;
RESPONSES;
FRAILTY;
HUMANS;
D O I:
10.1586/ECP.12.32
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Major advances produced by healthcare research have resulted in an increasing number of drugs that may be used to modify disease expression and improve quality of life. These discoveries have been used by clinical pharmacologists as a basis to identify new drug candidates and to develop strategies for their optimal delivery to maximize benefit while simultaneously minimizing adverse events. Unfortunately, many of these studies do not include sufficient older persons in whom most of these drug therapy interventions are likely to apply. This article examines selected physiological, pathological and healthcare interventional changes with age that impact clinical drug studies and the decision to use drugs as therapy in older adults. Clinical examples are provided that illustrate confounders to the accomplishment of an ideal outcome, the improved quality of life that remains for this population.
引用
收藏
页码:397 / 402
页数:6
相关论文